A Phase 1 interventional study of Esketamine and Cognitive Behavioral Therapy (CBT) in Depression, sponsored by Janssen Research & Development, LLC. Withdrawn at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing esketamine in Depression — 11 open to participants now, 12 under way, 1 of them phase 3. Esketamine · Depression.
Among the 28 studies testing esketamine in Depression, this one is the 28th largest by enrollment, is one of 4 that started in 2022, is one of 4 in phase 1, and was the 13th registered.
8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.
Browse Depression studies →11 of the 28 studies testing esketamine in Depression are open now, in 3 countries. Recruiting first, the newest first:
Min Su · Sites in China
Ages 13–17
Yale University · Sites in United States
Ages 18+
Royal North Shore Hospital · Sites in Australia
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–70
China Medical University, China · Sites in China
Ages 18–65 · Women only
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 3 · Phase 4 7
First in 2012; this study’s year is marked. 4 started in 2022.
Median enrollment 156 across the 28 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
19 studies in Depression by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 18 finished, 4 (22%) have results posted.
Among the 19 studies in Depression by Johnson & Johnson, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 1, and was the 19th registered.
Johnson & Johnson’s Depression studies by the year they started, since 2000.
4 of the studies testing esketamine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07179913The First Hospital of Jilin UniversityThe Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression | 2026-11-20 |
| NCT07247968Min SuSubanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | 2026-11-20 |
| NCT07367542Chinese PLA General HospitalEffect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery | 2027-02-01 |
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies testing esketamine in Depression, from their registry updates:
Among Johnson & Johnson’s 19 in Depression:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore feasibility of combining clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app with esketamine therapy in participants with Treatment-resistant Depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive esketamine nasal spray (Dose 1 or Dose 2) twice weekly for 4 weeks (Induction Phase), followed by once a week dose (Dose 1 or Dose 2) for 8 weeks (Maintenance Phase), in conjunction with an oral antidepressant. Clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app will be administered by a clinician following esketamine dosing once the participants is considered ready to engage in therapy, based on the clinician judgement of CBT readiness.
Drug: Esketamine · Behavioral: Cognitive Behavioral Therapy (CBT) · Drug: Antidepressant
Esketamine will be self-administered as nasal spray.
Also known as: SPRAVATO, JNJ-54135419, Non-Investigational Medicinal Product/Auxiliary Medicinal Product (NIMP/AxMP)
Clinician-directed CBT supplemented by the Mindset app will be administered.
Antidepressant will be administered orally.
System Usability Scale (SUS) Scores (Participants)
The SUS provides a reliable tool for measuring the usability of a wide variety of products and services, including hardware, software, mobile devices, websites, and applications. It consists of a 10-item questionnaire with five response options for respondents; from strongly agree to strongly disagree.
Time frame: Week 13
Net Promoter Scale Scores (Participants)
Net promoter score is a market research measure that asks respondents to rate the likelihood that they would recommend a company, product, or a service to a friend or colleague. Responses are on a rating on a scale of 0 (not at all likely) to 10 (extremely likely).
Time frame: Week 13
Exit Survey
Exit survey is a survey including ratings regarding participant impression of features of the Mindset app.
Time frame: Week 13
Time Spent on Mindset App
Time spent on Mindset app will be reported for participants.
Time frame: From Week 2 up to Week 13
Number of Times Mindset App Used
Number of times the Mindset app is used will be reported.
Time frame: From Week 2 up to Week 13
Pattern of Mindset App Used
Pattern of Mindset app usage will be reported.
Time frame: From Week 2 up to Week 13
CBT Therapist Assessment of Completion of Action Plan
Assessment of completion of action plan will be done by CBT therapists through rating on a 5-point likert scale of the participant's progress.
Time frame: From Week 2 up to Week 13
Participant Interviews
Optional qualitative feedback from study participants (participant's interviews) on the usefulness of the Mindset in conjunction with esketamine will be reported.
Time frame: Week 20
SUS Scores (CBT Therapists)
The SUS provides a reliable tool for measuring the usability of a wide variety of products and services, including hardware, software, mobile devices, websites, and applications. It consists of a 10-item questionnaire with five response options for respondents; from strongly agree to strongly disagree.
Time frame: Up to 14 months (at the end of study)
Net Promoter Scale Scores (CBT Therapists)
Net promoter score is a market research measure that asks respondents to rate the likelihood that they would recommend a company, product, or a service to a friend or colleague. Responses are on a rating on a scale of 0 (not at all likely) to 10 (extremely likely).
Time frame: Up to 14 months (at the end of study)
Frequency of Use of Clinician Dashboard Used
Frequency of use of clinician dashboard will be reported.
Time frame: From Week 2 up to Week 13
Clinician Feedback
Qualitative feedback on clinician dashboard and participant use of the mindset app in conjunction with esketamine (clinician feedback) will be reported.
Time frame: Up to 14 months
Percentage of Participants Able to Engage in CBT
Percentage of participants able to engage in CBT on the day of dosing for each week of the study and overall will be reported.
Time frame: From Week 2 up to Week 13
Timing of CBT Readiness after Dosing
Timing of CBT readiness after dosing will be reported. Determination of readiness will be based on clinician judgement of CBT readiness to engage in CBT based on alertness and ability to concentrate after dosing.
Time frame: From Week 2 up to Week 13
Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Scale Score
The MOAA/S will be used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American Society of Anesthesiologists (ASA) continuum. The MOAA/S scores range from 0=no response to painful stimulus (corresponds to ASA continuum for general anesthesia) to 5=readily responds to name spoken in normal tone (awake; corresponds to ASA continuum for minimal sedation).
Time frame: Pre-dose, 40 minutes and 90 minutes post-dose up to Week 4
Clinician Administered Dissociative States Scale (CADSS) Score
The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. The CADSS consists of 23 subjective items, divided into 3 components: depersonalization (Items 3 to 7, 20, and 23), derealization (Items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia (Items 14, 15, and 22). Participant's responses are coded on a 5-point scale (0=not at all through to 4=extremely). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition
Time frame: Pre-dose, 40 minutes and 90 minutes post-dose up to Week 4
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment
Time frame: From Week 2 up to Week 13
Number of Participants with Abnormalities in Vital Signs
Number of participants with abnormalities in vital signs (pulse/heart rate, blood pressure, and body temperature) will be reported.
Time frame: From Week 2 up to Week 13
Columbia Suicide Severity Rating (C-SSRS) Score
C-SSRS is semi structured clinician-administered questionnaire designed to solicit the occurrence, severity, and frequency of suicide-related ideation and behaviors. The maximum score assigned for each participant will also be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity.
Time frame: Up to Week 13
Clinical Global Assessment of Discharge Readiness (CGADR) Score
The CGADR will be used to measure the participant's current clinical status and is the clinician's assessment of the readiness to be discharged from the study site. The clinician will answer "Yes" or "No" to the question "Is the participant considered ready to be discharged based on their overall clinical status (example, sedation, blood pressure, and other adverse events)?"
Time frame: From Week 2 up to Week 13
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Start is estimated for Sep 2022; primary completion for Jun 2023, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Janssen Research & Development, LLC →